Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(21):1652; doi:10.1093/jnci/94.21.1652
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by de Lemos, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lemos, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 21, 1652, November 6, 2002
© 2002 Oxford University Press

CORRESPONDENCE

Re: Adherence to Therapy With Oral Antineoplastic Agents

Mário de Lemos

Correspondence to: Mário de Lemos, Pharm.D., Provincial Systemic Therapy Program, British Columbia Cancer Agency, 600 West 10th Ave., Vancouver, BC V5Z 4E6, Canada (e-mail: mdelemos@bccancer.bc.ca).

The first 10% of the full text of this article appears below.

Partridge et al. provided an excellent and timely review on patient compliance issues of prescribed oral therapy (1). This important area merits the attention of every oncology clinician, in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?